NorthWest Biotherapeutics Inc (NWBO)

[branster]

Merck needs to strike a deal with us.

Merck KGaA fails key lung cancer trial; Offerings INO ONCS

Price and Volume Movers
Merck KGaA and GlaxoSmithKline plc (NYSE: GSK) announced that their Phase 3 INTR@PID Lung 037 trial of bintrafusp alfa in the first-line treatment of patients with late-stage non-small cell lung cancer (NSCLC), will be discontinued following an Independent Data Monitoring Committee review which determined the trial was unlikely to meet the primary efficacy endpoint. The drug was trialed against Merck & Co's blockbuster immunotherapy, Keytruda. Shares of Glaxo closed down 1.4% to $38.02.